Abstract

ADMET Technologies in Drug Design and Discovery: Helping the Medicinal Chemist in Optimal Drug Design

Subrahmanyam Vangala, Founder and Chief Executive Officer, ReaGene Biosciences Private Limited

Drug Design during Medicinal Chemistry not only involves SAR activities of the pharmacological target but also involves SAR activities of ADME and Toxicology (ADMET). If the ADMET principles are not rigorously applied during the drug design process, these New Chemical Entities (NCEs) after reaching clinical development face several hurdles with many failures that could be financially crippling and hinder the commercial launch of the NCEs. Recent advances in understanding the biochemistry of drug metabolizing enzymes, drug transporters, species differences and pharmacogenetics in metabolism and transport, and mechanistic understanding of drug-drug Interactions have become very critical in the translation of preclinical Information of an NCE into meaningful clinical outcome. The use of microfluidic chip technologies also looks very promising in translating preclinical information to clinical information. This talk will focus on how ADMET technologies have evolved in the past twenty years while becoming very critical for Medicinal Chemists to design novel NCEs.